Biological Response Modifiers Advisory Committee

Executive Summary

FDA announces creation of the new panel within the Center for Biologics Evaluation and Research. The committee "will review and evaluate data relating to the safety, effectiveness, and appropriate use of biological response modifiers which are intended for use in the prevention and treatment of a broad spectrum of human diseases," a Dec. 8 Federal Register notice says. The agency is also accepting nominations for nine voting members to serve on the panel. Nominations should be sent to Jack Gertzog, Advisors and Consultants Staff, CBER, and should be received by Feb. 6, 1989....